Alzheimer's disease: a review for the ophthalmologist (Q34293009)

1 August 2017

1 reference

title

Alzheimer's disease: a review for the ophthalmologist (English)

1 reference

1 August 2017

0 references

Holroyd S

1 reference

1 August 2017

Shepherd ML

series ordinal

1 reference

1 August 2017

publication date

1 May 2001

1 reference

1 August 2017

published in

Survey of Ophthalmology

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

516-524

1 reference

Visual field defects in Alzheimer's disease patients may reflect differential pathology in the primary visual cortex.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Retinal Degeneration in the Macula of Patients with Alzheimer's Diseasea

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Patterns of brain activation in people at risk for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Biochemical studies of nerve cells and energy metabolism in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Alzheimer's disease: areal and laminar pathology in the occipital isocortex

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Lecithin and memory training in suspected Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Visual disturbances with focal progressive dementing disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Visual dysfunction in Alzheimer's disease: relation to normal aging

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Visual Function in Alzheimer's Disease and Normal Aginga

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Cholinesterase inhibitors: A new class of psychotropic compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Physostigmine ameliorates the delusions of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Advances and challenges in the prevention and treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Tacrine in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

The US economic and social costs of Alzheimer's disease revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

1 reference

7 January 2021

The association between head trauma and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Epidemiology of dementia and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Optic-nerve degeneration in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Object recognition deficit in Alzheimer's disease: Possible disconnection of the occipito-temporal component of the visual system

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

A Study of Visual Hallucinations in Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Occipital atrophy is associated with visual hallucinations in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Tolerance and safety of vitamin E: A toxicological position report

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Diagnosis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Alzheimer's disease with prominent visual symptoms. Clinical and metabolic evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: a preliminary positron emission tomography study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: a quantitative study of visual and auditory cortices

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Complex visual disturbances in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Assessment of behavioral and affective symptoms in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Personality alterations in dementia of the Alzheimer type: a three-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

The impact of dementia on the family

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Is senile dementia "age-related" or "ageing-related"?--evidence from meta-analysis of dementia prevalence in the oldest old

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Retinocalcarine function in Alzheimer's disease. A clinical and electrophysiological study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Prevalence of mental illness in a community nursing home.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Genetic dissection of Alzheimer disease, a heterogeneous disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Overview of clinical trials of hydergine in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Estrogen and Alzheimer disease: plausible theory, negative clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Researchers find evidence of a new gene for late-onset Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Risk of Alzheimer's disease and duration of NSAID use.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Mental disorders in the nursing home: another perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Choline chloride fails to improve cognition in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Presenilins and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Major depression in primary dementia. Clinical and neuropathologic correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

The neuropathology of aminergic nuclei in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

Visual hallucinations as the first symptom of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

The involvement of astrocytes and an acute phase response in the amyloid deposition of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2801%2900193-X

7 January 2021

10.1016/S0039-6257(01)00193-X

Identifiers

DOI

1 reference

1 August 2017

1 reference